Natural ghrelin in advanced cancer patients with cachexia, a case series
Background Natural ghrelin, a peptide growth hormone secretagogue, has a therapeutic potential in cachexia. We designed a dose‐finding trial of subcutaneous natural ghrelin to improve nutritional intake (NI) in advanced cancer patients. Methods Advanced cancer patients with cachexia management (symp...
Saved in:
| Published in: | Journal of cachexia, sarcopenia and muscle Vol. 12; no. 2; pp. 506 - 516 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Germany
John Wiley & Sons, Inc
01.04.2021
John Wiley and Sons Inc Wiley |
| Subjects: | |
| ISSN: | 2190-5991, 2190-6009, 2190-6009 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
Natural ghrelin, a peptide growth hormone secretagogue, has a therapeutic potential in cachexia. We designed a dose‐finding trial of subcutaneous natural ghrelin to improve nutritional intake (NI) in advanced cancer patients.
Methods
Advanced cancer patients with cachexia management (symptom management, physiotherapy, nutritional, and psychosocial support) started with ghrelin at 32 μg/kg body weight, followed by 50% dose increases. Patients self‐injected ghrelin twice daily for 4 days followed by a wash‐out period. After reaching the primary endpoint, maximal NI (minimal dose for maximal NI), a maintenance period followed during which patients injected 10 doses of ghrelin per week. Safety parameters, NI, and cachexia outcomes (symptoms, narratives, muscle mass, and strength) were measured over 6 weeks.
Results
Ten patients with metastatic solid tumours were included, and six (100% male, mean age 61.8 ± 8.5 SD) received ghrelin. Minimal dose for maximal NI was reached in four patients. Three patients reached the end‐of study visit. Ghrelin was well tolerated with variable results on appetite and eating‐related symptoms but a positive effect in the narratives. Mean Functional Assessment of Appetite & Cachexia Therapy score was 6.8 points lower at final measurement compared with baseline, t(5) = 5.98, P < .01. Muscle mass was stable in two patients and increased in one patient, and muscle strength was stable in three patients. Subjective tolerability was high. Patients showed a fluctuating trajectory, and median survival was 88 days (51–412 days).
Conclusions
Ghrelin was safe in advanced patients with cancer cachexia without dose‐limiting toxicity and well tolerated. The intervention was very complex, and the number of patients included was small. There was a positive effect on nutritional intake and patient narratives. |
|---|---|
| AbstractList | Background
Natural ghrelin, a peptide growth hormone secretagogue, has a therapeutic potential in cachexia. We designed a dose‐finding trial of subcutaneous natural ghrelin to improve nutritional intake (NI) in advanced cancer patients.
Methods
Advanced cancer patients with cachexia management (symptom management, physiotherapy, nutritional, and psychosocial support) started with ghrelin at 32 μg/kg body weight, followed by 50% dose increases. Patients self‐injected ghrelin twice daily for 4 days followed by a wash‐out period. After reaching the primary endpoint, maximal NI (minimal dose for maximal NI), a maintenance period followed during which patients injected 10 doses of ghrelin per week. Safety parameters, NI, and cachexia outcomes (symptoms, narratives, muscle mass, and strength) were measured over 6 weeks.
Results
Ten patients with metastatic solid tumours were included, and six (100% male, mean age 61.8 ± 8.5 SD) received ghrelin. Minimal dose for maximal NI was reached in four patients. Three patients reached the end‐of study visit. Ghrelin was well tolerated with variable results on appetite and eating‐related symptoms but a positive effect in the narratives. Mean Functional Assessment of Appetite & Cachexia Therapy score was 6.8 points lower at final measurement compared with baseline, t(5) = 5.98, P < .01. Muscle mass was stable in two patients and increased in one patient, and muscle strength was stable in three patients. Subjective tolerability was high. Patients showed a fluctuating trajectory, and median survival was 88 days (51–412 days).
Conclusions
Ghrelin was safe in advanced patients with cancer cachexia without dose‐limiting toxicity and well tolerated. The intervention was very complex, and the number of patients included was small. There was a positive effect on nutritional intake and patient narratives. BackgroundNatural ghrelin, a peptide growth hormone secretagogue, has a therapeutic potential in cachexia. We designed a dose-finding trial of subcutaneous natural ghrelin to improve nutritional intake (NI) in advanced cancer patients.MethodsAdvanced cancer patients with cachexia management (symptom management, physiotherapy, nutritional, and psychosocial support) started with ghrelin at 32 μg/kg body weight, followed by 50% dose increases. Patients self-injected ghrelin twice daily for 4 days followed by a wash-out period. After reaching the primary endpoint, maximal NI (minimal dose for maximal NI), a maintenance period followed during which patients injected 10 doses of ghrelin per week. Safety parameters, NI, and cachexia outcomes (symptoms, narratives, muscle mass, and strength) were measured over 6 weeks.ResultsTen patients with metastatic solid tumours were included, and six (100% male, mean age 61.8 ± 8.5 SD) received ghrelin. Minimal dose for maximal NI was reached in four patients. Three patients reached the end-of study visit. Ghrelin was well tolerated with variable results on appetite and eating-related symptoms but a positive effect in the narratives. Mean Functional Assessment of Appetite & Cachexia Therapy score was 6.8 points lower at final measurement compared with baseline, t(5) = 5.98, P < .01. Muscle mass was stable in two patients and increased in one patient, and muscle strength was stable in three patients. Subjective tolerability was high. Patients showed a fluctuating trajectory, and median survival was 88 days (51–412 days).ConclusionsGhrelin was safe in advanced patients with cancer cachexia without dose-limiting toxicity and well tolerated. The intervention was very complex, and the number of patients included was small. There was a positive effect on nutritional intake and patient narratives. Natural ghrelin, a peptide growth hormone secretagogue, has a therapeutic potential in cachexia. We designed a dose-finding trial of subcutaneous natural ghrelin to improve nutritional intake (NI) in advanced cancer patients.BACKGROUNDNatural ghrelin, a peptide growth hormone secretagogue, has a therapeutic potential in cachexia. We designed a dose-finding trial of subcutaneous natural ghrelin to improve nutritional intake (NI) in advanced cancer patients.Advanced cancer patients with cachexia management (symptom management, physiotherapy, nutritional, and psychosocial support) started with ghrelin at 32 μg/kg body weight, followed by 50% dose increases. Patients self-injected ghrelin twice daily for 4 days followed by a wash-out period. After reaching the primary endpoint, maximal NI (minimal dose for maximal NI), a maintenance period followed during which patients injected 10 doses of ghrelin per week. Safety parameters, NI, and cachexia outcomes (symptoms, narratives, muscle mass, and strength) were measured over 6 weeks.METHODSAdvanced cancer patients with cachexia management (symptom management, physiotherapy, nutritional, and psychosocial support) started with ghrelin at 32 μg/kg body weight, followed by 50% dose increases. Patients self-injected ghrelin twice daily for 4 days followed by a wash-out period. After reaching the primary endpoint, maximal NI (minimal dose for maximal NI), a maintenance period followed during which patients injected 10 doses of ghrelin per week. Safety parameters, NI, and cachexia outcomes (symptoms, narratives, muscle mass, and strength) were measured over 6 weeks.Ten patients with metastatic solid tumours were included, and six (100% male, mean age 61.8 ± 8.5 SD) received ghrelin. Minimal dose for maximal NI was reached in four patients. Three patients reached the end-of study visit. Ghrelin was well tolerated with variable results on appetite and eating-related symptoms but a positive effect in the narratives. Mean Functional Assessment of Appetite & Cachexia Therapy score was 6.8 points lower at final measurement compared with baseline, t(5) = 5.98, P < .01. Muscle mass was stable in two patients and increased in one patient, and muscle strength was stable in three patients. Subjective tolerability was high. Patients showed a fluctuating trajectory, and median survival was 88 days (51-412 days).RESULTSTen patients with metastatic solid tumours were included, and six (100% male, mean age 61.8 ± 8.5 SD) received ghrelin. Minimal dose for maximal NI was reached in four patients. Three patients reached the end-of study visit. Ghrelin was well tolerated with variable results on appetite and eating-related symptoms but a positive effect in the narratives. Mean Functional Assessment of Appetite & Cachexia Therapy score was 6.8 points lower at final measurement compared with baseline, t(5) = 5.98, P < .01. Muscle mass was stable in two patients and increased in one patient, and muscle strength was stable in three patients. Subjective tolerability was high. Patients showed a fluctuating trajectory, and median survival was 88 days (51-412 days).Ghrelin was safe in advanced patients with cancer cachexia without dose-limiting toxicity and well tolerated. The intervention was very complex, and the number of patients included was small. There was a positive effect on nutritional intake and patient narratives.CONCLUSIONSGhrelin was safe in advanced patients with cancer cachexia without dose-limiting toxicity and well tolerated. The intervention was very complex, and the number of patients included was small. There was a positive effect on nutritional intake and patient narratives. Abstract Background Natural ghrelin, a peptide growth hormone secretagogue, has a therapeutic potential in cachexia. We designed a dose‐finding trial of subcutaneous natural ghrelin to improve nutritional intake (NI) in advanced cancer patients. Methods Advanced cancer patients with cachexia management (symptom management, physiotherapy, nutritional, and psychosocial support) started with ghrelin at 32 μg/kg body weight, followed by 50% dose increases. Patients self‐injected ghrelin twice daily for 4 days followed by a wash‐out period. After reaching the primary endpoint, maximal NI (minimal dose for maximal NI), a maintenance period followed during which patients injected 10 doses of ghrelin per week. Safety parameters, NI, and cachexia outcomes (symptoms, narratives, muscle mass, and strength) were measured over 6 weeks. Results Ten patients with metastatic solid tumours were included, and six (100% male, mean age 61.8 ± 8.5 SD) received ghrelin. Minimal dose for maximal NI was reached in four patients. Three patients reached the end‐of study visit. Ghrelin was well tolerated with variable results on appetite and eating‐related symptoms but a positive effect in the narratives. Mean Functional Assessment of Appetite & Cachexia Therapy score was 6.8 points lower at final measurement compared with baseline, t(5) = 5.98, P < .01. Muscle mass was stable in two patients and increased in one patient, and muscle strength was stable in three patients. Subjective tolerability was high. Patients showed a fluctuating trajectory, and median survival was 88 days (51–412 days). Conclusions Ghrelin was safe in advanced patients with cancer cachexia without dose‐limiting toxicity and well tolerated. The intervention was very complex, and the number of patients included was small. There was a positive effect on nutritional intake and patient narratives. Natural ghrelin, a peptide growth hormone secretagogue, has a therapeutic potential in cachexia. We designed a dose-finding trial of subcutaneous natural ghrelin to improve nutritional intake (NI) in advanced cancer patients. Advanced cancer patients with cachexia management (symptom management, physiotherapy, nutritional, and psychosocial support) started with ghrelin at 32 μg/kg body weight, followed by 50% dose increases. Patients self-injected ghrelin twice daily for 4 days followed by a wash-out period. After reaching the primary endpoint, maximal NI (minimal dose for maximal NI), a maintenance period followed during which patients injected 10 doses of ghrelin per week. Safety parameters, NI, and cachexia outcomes (symptoms, narratives, muscle mass, and strength) were measured over 6 weeks. Ten patients with metastatic solid tumours were included, and six (100% male, mean age 61.8 ± 8.5 SD) received ghrelin. Minimal dose for maximal NI was reached in four patients. Three patients reached the end-of study visit. Ghrelin was well tolerated with variable results on appetite and eating-related symptoms but a positive effect in the narratives. Mean Functional Assessment of Appetite & Cachexia Therapy score was 6.8 points lower at final measurement compared with baseline, t(5) = 5.98, P < .01. Muscle mass was stable in two patients and increased in one patient, and muscle strength was stable in three patients. Subjective tolerability was high. Patients showed a fluctuating trajectory, and median survival was 88 days (51-412 days). Ghrelin was safe in advanced patients with cancer cachexia without dose-limiting toxicity and well tolerated. The intervention was very complex, and the number of patients included was small. There was a positive effect on nutritional intake and patient narratives. |
| Author | Strasser, Florian Oberholzer, Rolf Blum, David Wolf‐Linder, Susanne Hundsberger, Thomas Brändle, Michael |
| AuthorAffiliation | 4 Wolfson Palliative Care Research Centre, Hull York Medical School Hull University Hull UK 1 Oncological Palliative Medicine, Clinic Oncology/Hematology Cantonal Hospital St. Gallen St. Gallen Switzerland 6 Neurology Cantonal Hospital St. Gallen St. Gallen Switzerland 3 School of Health Professions, Institute of Nursing Zurich University of Applied Sciences Winterthur Switzerland 5 Internal Medicine Cantonal Hospital St. Gallen St. Gallen Switzerland 2 Competence Center Palliative Care, Department of Radiation Oncology Universitätsspital Zürich Zürich Switzerland |
| AuthorAffiliation_xml | – name: 3 School of Health Professions, Institute of Nursing Zurich University of Applied Sciences Winterthur Switzerland – name: 2 Competence Center Palliative Care, Department of Radiation Oncology Universitätsspital Zürich Zürich Switzerland – name: 5 Internal Medicine Cantonal Hospital St. Gallen St. Gallen Switzerland – name: 4 Wolfson Palliative Care Research Centre, Hull York Medical School Hull University Hull UK – name: 6 Neurology Cantonal Hospital St. Gallen St. Gallen Switzerland – name: 1 Oncological Palliative Medicine, Clinic Oncology/Hematology Cantonal Hospital St. Gallen St. Gallen Switzerland |
| Author_xml | – sequence: 1 givenname: David orcidid: 0000-0003-2473-7069 surname: Blum fullname: Blum, David email: david.blum@usz.ch organization: Universitätsspital Zürich – sequence: 2 givenname: Susanne surname: Wolf‐Linder fullname: Wolf‐Linder, Susanne organization: Hull University – sequence: 3 givenname: Rolf surname: Oberholzer fullname: Oberholzer, Rolf organization: Cantonal Hospital St. Gallen – sequence: 4 givenname: Michael surname: Brändle fullname: Brändle, Michael organization: Cantonal Hospital St. Gallen – sequence: 5 givenname: Thomas surname: Hundsberger fullname: Hundsberger, Thomas organization: Cantonal Hospital St. Gallen – sequence: 6 givenname: Florian surname: Strasser fullname: Strasser, Florian organization: Cantonal Hospital St. Gallen |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33452750$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kltrFDEUx4NUbK198QPIgC8ibj25TC4vgixqK1Uf1OeQSTK7WWYnazLT2m9vprMVW6QhcELyO_-c21N00MfeI_QcwykGIG83Nm9PMeG1eoSOCFaw4ADqYH-ulcKH6CTnDZTFOOY1PEGHlLKaiBqO0NlXM4zJdNVqnXwX-qps4y5Nb72r7GRStTND8P2Qq6swrMulXfvfwbypTDlnX2Wfgs_P0OPWdNmf7O0x-vnxw4_l2eLi26fz5fuLheWg1II0nmNKgEkrqGhtw1ijjIAGy9Yap6SjxOKWKkLBQSEF5q71jWywIo0AeozOZ10XzUbvUtiadK2jCfrmIqaVNmkItvPaWmEFY5K2hjFgVFIFBjsGlHNnwBStd7PWbmy23tmSZCnFHdG7L31Y61W81BI4LjJF4NVeIMVfo8-D3oZsfdeZ3scxa8KErFXN6wl9eQ_dxDH1pVSaSAIlNsnwg1SNOZa0_FqoF__G_Tfg27YWAGbApphz8q22YShdjFMaodMY9DQ8ehoefTM8xeX1PZdb1f_CeIavQuevHyD15-X3L7PPH-1x0a4 |
| CitedBy_id | crossref_primary_10_3390_ijms23105380 crossref_primary_10_1186_s12957_025_03846_7 crossref_primary_10_1039_D4FO06083K crossref_primary_10_1002_cam4_6549 crossref_primary_10_3390_ijms221910571 crossref_primary_10_1007_s10330_022_0611_1 crossref_primary_10_3389_fonc_2023_1255112 crossref_primary_10_3390_ijms22168491 crossref_primary_10_3390_nu14194191 crossref_primary_10_1186_s43094_024_00726_x crossref_primary_10_1007_s12325_022_02074_9 crossref_primary_10_3390_biom12040483 crossref_primary_10_3390_biomedicines11123276 |
| Cites_doi | 10.1200/JCO.1993.11.3.570 10.1097/SPC.0000000000000387 10.1007/s00520-013-1894-4 10.1007/s005200050281 10.1016/j.physbeh.2011.03.027 10.1177/0269216307085183 10.1152/japplphysiol.00744.2004 10.1007/s00520-016-3144-z 10.1007/s00280-005-0179-0 10.1038/45230 10.1002/jcsm.12083 10.1002/jcsm.12501 10.1016/S0149-2918(05)80001-3 10.1016/S0889-8588(02)00011-4 10.1007/s13539-012-0099-x 10.1016/S0959-8049(97)10090-9 10.1139/H08-075 10.1016/j.jpainsymman.2006.09.024 10.1093/annonc/mdu086 10.1016/S1470-2045(10)70218-7 10.1038/sj.bjc.6604148 10.1210/jc.2003-031768 10.1177/0269216307076346 10.1200/JCO.2005.01.8010 10.1002/jcsm.12254 10.1016/S1470-2045(15)00558-6 10.1177/082585979100700202 |
| ContentType | Journal Article |
| Copyright | 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders. 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders – notice: 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders. – notice: 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1002/jcsm.12659 |
| DatabaseName | Wiley Online Library Open Access CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest One Health & Nursing ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database Publicly Available Content Database MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Individually dose‐optimized (dose escalation) subcutaneous |
| EISSN | 2190-6009 |
| EndPage | 516 |
| ExternalDocumentID | oai_doaj_org_article_cc7c74483fa440438390a1d40366da0a PMC8061403 33452750 10_1002_jcsm_12659 JCSM12659 |
| Genre | article Journal Article |
| GrantInformation_xml | – fundername: Gastrotech Pharma A/S – fundername: Bachem |
| GroupedDBID | --- 0R~ 1OC 24P 2VQ 4.4 40G 53G 5VS 7X7 8FI 8FJ AAHHS AAKDD AAZKR ABUWG ACCFJ ACCMX ACXQS ADBBV ADINQ ADKYN ADPDF ADRAZ ADZMN ADZOD AEEZP AENEX AEQDE AFKRA AHBYD AHSBF AIWBW AJBDE ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMKLP AOIJS AVUZU AZFZN BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU DIK EBS EJD EMOBN FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH ITC KQ8 M48 M~E O9- OK1 OVD OVEED PIMPY PQQKQ PROAC RPM RSV SMD SOJ U2A UKHRP WIN ZOVNA AAFWJ AAMMB AAYXX AEFGJ AFFHD AFPKN AGXDD AIDQK AIDYY CITATION PHGZM PHGZT NPM 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c6099-2be6132048c737fcb44b9a70b18fcad98d32c1f39230d0132716dfeb8b192b703 |
| IEDL.DBID | 7X7 |
| ISICitedReferencesCount | 15 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000607783100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2190-5991 2190-6009 |
| IngestDate | Fri Oct 03 12:43:50 EDT 2025 Tue Nov 04 01:42:58 EST 2025 Fri Sep 05 10:32:15 EDT 2025 Tue Oct 07 07:12:23 EDT 2025 Tue Oct 07 06:53:37 EDT 2025 Wed Feb 19 02:28:39 EST 2025 Sat Nov 29 04:06:39 EST 2025 Tue Nov 18 22:13:47 EST 2025 Wed Jan 22 16:30:40 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Appetite Cancer cachexia Ghrelin Muscle mass |
| Language | English |
| License | Attribution 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c6099-2be6132048c737fcb44b9a70b18fcad98d32c1f39230d0132716dfeb8b192b703 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-2473-7069 |
| OpenAccessLink | https://www.proquest.com/docview/2820839841?pq-origsite=%requestingapplication% |
| PMID | 33452750 |
| PQID | 2516183033 |
| PQPubID | 4370305 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_cc7c74483fa440438390a1d40366da0a pubmedcentral_primary_oai_pubmedcentral_nih_gov_8061403 proquest_miscellaneous_2478595653 proquest_journals_2820839841 proquest_journals_2516183033 pubmed_primary_33452750 crossref_citationtrail_10_1002_jcsm_12659 crossref_primary_10_1002_jcsm_12659 wiley_primary_10_1002_jcsm_12659_JCSM12659 |
| PublicationCentury | 2000 |
| PublicationDate | April 2021 |
| PublicationDateYYYYMMDD | 2021-04-01 |
| PublicationDate_xml | – month: 04 year: 2021 text: April 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | Germany |
| PublicationPlace_xml | – name: Germany – name: Heidelberg – name: Hoboken |
| PublicationTitle | Journal of cachexia, sarcopenia and muscle |
| PublicationTitleAlternate | J Cachexia Sarcopenia Muscle |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
| References | 2002; 16 1980; 69 2017; 8 2015; 6 2013; 4 2013; 21 2019; 10 2000; 8 2006; 58 2004; 89 2014; 25 2008; 98 2011; 12 2008; 33 2016; 17 2007; 33 1999; 402 2005; 23 1991; 7 2011; 105 2004; 97 1993; 11 2008; 22 2018; 12 2007; 21 1998; 34 2016; 24 e_1_2_9_11_1 e_1_2_9_10_1 e_1_2_9_13_1 e_1_2_9_12_1 e_1_2_9_15_1 e_1_2_9_14_1 e_1_2_9_17_1 e_1_2_9_16_1 e_1_2_9_19_1 e_1_2_9_18_1 e_1_2_9_20_1 e_1_2_9_22_1 e_1_2_9_21_1 e_1_2_9_24_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 e_1_2_9_27_1 |
| References_xml | – volume: 69 start-page: 491 year: 1980 end-page: 497 article-title: Prognostic effect of weight loss prior to chemotherapy in cancer patients publication-title: Am J Med – volume: 33 start-page: 676 year: 2007 end-page: 685 article-title: Objective physical activity and self‐reported quality of life in patients receiving palliative chemotherapy publication-title: J Pain Symptom Manage – volume: 25 start-page: 1635 year: 2014 end-page: 1642 article-title: Validation of the consensus‐definition for cancer cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC‐CSA) publication-title: Ann Oncol – volume: 11 start-page: 570 year: 1993 end-page: 579 article-title: The Functional Assessment of Cancer Therapy scale: development and validation of the general measure publication-title: J Clin Oncol – volume: 22 start-page: 13 year: 2008 end-page: 32 article-title: Fatigue in palliative care patients—an EAPC approach publication-title: Palliat Med – volume: 8 start-page: 991 year: 2017 end-page: 998 article-title: Acylated ghrelin treatment normalizes skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rat chronic heart failure publication-title: J Cachexia Sarcopenia Muscle – volume: 7 start-page: 6 year: 1991 end-page: 9 article-title: The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients publication-title: J Palliat Care – volume: 23 start-page: 8500 year: 2005 end-page: 8511 article-title: Systematic review of the treatment of cancer‐associated anorexia and weight loss publication-title: J Clin Oncol – volume: 21 start-page: 129 year: 2007 end-page: 137 article-title: Fighting a losing battle: eating‐related distress of men with advanced cancer and their female partners. A mixed‐methods study publication-title: Palliat Med – volume: 12 start-page: 489 year: 2011 end-page: 495 article-title: Definition and classification of cancer cachexia: an international consensus publication-title: Lancet Oncol – volume: 6 start-page: 272 year: 2015 end-page: 274 article-title: Request for regulatory guidance for cancer cachexia intervention trials publication-title: J Cachexia Sarcopenia Muscle – volume: 10 start-page: 1143 year: 2019 end-page: 1145 article-title: Ethical guidelines for publishing in the : update 2019 publication-title: J Cachexia Sarcopenia Muscle – volume: 58 start-page: 326 year: 2006 end-page: 333 article-title: Ghrelin alleviates cancer chemotherapy‐associated dyspepsia in rodents publication-title: Cancer Chemother Pharmacol – volume: 4 start-page: 55 year: 2013 end-page: 61 article-title: Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case‐control study publication-title: J Cachexia Sarcopenia Muscle – volume: 8 start-page: 175 year: 2000 end-page: 179 article-title: The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients publication-title: Support Care Cancer – volume: 89 start-page: 2832 year: 2004 end-page: 2836 article-title: Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo‐controlled trial publication-title: J Clin Endocrinol Metabol – volume: 34 start-page: 503 year: 1998 end-page: 509 article-title: Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? publication-title: Eur J Cancer – volume: 402 start-page: 656 year: 1999 end-page: 660 article-title: Ghrelin is a growth‐hormone‐releasing acylated peptide from stomach publication-title: Nature – volume: 24 start-page: 3495 year: 2016 end-page: 3505 article-title: Anamorelin (ONO‐7643) in Japanese patients with non‐small cell lung cancer and cachexia: results of a randomized phase 2 trial publication-title: Support Care Cancer – volume: 98 start-page: 300 year: 2008 end-page: 308 article-title: Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer‐related anorexia/cachexia: a randomised, placebo‐controlled, double‐blind, double‐crossover study publication-title: Br J Cancer – volume: 12 start-page: 445 year: 2018 end-page: 452 article-title: Endpoints in clinical trials in cancer cachexia: where to start? publication-title: Curr Opin Support Palliat Care – volume: 21 start-page: 3261 year: 2013 end-page: 3270 article-title: Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients publication-title: Support Care Cancer – volume: 105 start-page: 43 year: 2011 end-page: 51 article-title: Ghrelin‐induced hypothermia: a physiological basis but no clinical risk publication-title: Physiol Behav – volume: 97 start-page: 2333 year: 2004 end-page: 2338 article-title: Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross‐sectional image publication-title: J Appl Physiol (1985) – volume: 16 start-page: 589 year: 2002 end-page: 617 article-title: Update on anorexia and cachexia publication-title: Hematol Oncol Clin North Am – volume: 33 start-page: 997 year: 2008 end-page: 1006 article-title: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care publication-title: Appl Physiol Nutr Metab – volume: 17 start-page: 519 year: 2016 end-page: 531 article-title: Anamorelin in patients with non‐small‐cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double‐blind, phase 3 trials publication-title: Lancet Oncol – ident: e_1_2_9_18_1 doi: 10.1200/JCO.1993.11.3.570 – ident: e_1_2_9_27_1 doi: 10.1097/SPC.0000000000000387 – ident: e_1_2_9_21_1 doi: 10.1007/s00520-013-1894-4 – ident: e_1_2_9_7_1 doi: 10.1007/s005200050281 – ident: e_1_2_9_23_1 doi: 10.1016/j.physbeh.2011.03.027 – ident: e_1_2_9_5_1 doi: 10.1177/0269216307085183 – ident: e_1_2_9_20_1 doi: 10.1152/japplphysiol.00744.2004 – ident: e_1_2_9_25_1 doi: 10.1007/s00520-016-3144-z – ident: e_1_2_9_13_1 doi: 10.1007/s00280-005-0179-0 – ident: e_1_2_9_12_1 doi: 10.1038/45230 – ident: e_1_2_9_26_1 doi: 10.1002/jcsm.12083 – ident: e_1_2_9_28_1 doi: 10.1002/jcsm.12501 – ident: e_1_2_9_3_1 doi: 10.1016/S0149-2918(05)80001-3 – ident: e_1_2_9_2_1 doi: 10.1016/S0889-8588(02)00011-4 – ident: e_1_2_9_10_1 doi: 10.1007/s13539-012-0099-x – ident: e_1_2_9_4_1 doi: 10.1016/S0959-8049(97)10090-9 – ident: e_1_2_9_19_1 doi: 10.1139/H08-075 – ident: e_1_2_9_22_1 doi: 10.1016/j.jpainsymman.2006.09.024 – ident: e_1_2_9_8_1 doi: 10.1093/annonc/mdu086 – ident: e_1_2_9_9_1 doi: 10.1016/S1470-2045(10)70218-7 – ident: e_1_2_9_16_1 doi: 10.1038/sj.bjc.6604148 – ident: e_1_2_9_14_1 doi: 10.1210/jc.2003-031768 – ident: e_1_2_9_6_1 doi: 10.1177/0269216307076346 – ident: e_1_2_9_11_1 doi: 10.1200/JCO.2005.01.8010 – ident: e_1_2_9_15_1 doi: 10.1002/jcsm.12254 – ident: e_1_2_9_24_1 doi: 10.1016/S1470-2045(15)00558-6 – ident: e_1_2_9_17_1 doi: 10.1177/082585979100700202 |
| SSID | ssj0000461650 |
| Score | 2.3261135 |
| Snippet | Background
Natural ghrelin, a peptide growth hormone secretagogue, has a therapeutic potential in cachexia. We designed a dose‐finding trial of subcutaneous... Natural ghrelin, a peptide growth hormone secretagogue, has a therapeutic potential in cachexia. We designed a dose-finding trial of subcutaneous natural... BackgroundNatural ghrelin, a peptide growth hormone secretagogue, has a therapeutic potential in cachexia. We designed a dose‐finding trial of subcutaneous... BackgroundNatural ghrelin, a peptide growth hormone secretagogue, has a therapeutic potential in cachexia. We designed a dose-finding trial of subcutaneous... Abstract Background Natural ghrelin, a peptide growth hormone secretagogue, has a therapeutic potential in cachexia. We designed a dose‐finding trial of... |
| SourceID | doaj pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 506 |
| SubjectTerms | Anorexia Appetite Cancer cachexia Cancer therapies Chemotherapy Counseling Drug dosages Food Ghrelin Growth hormones Muscle mass Nutrition Nutritionists Original Patients Steroids |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA9SRHwRv11tJaIvimezm899rMVSxB6CCn0L-dQT3cptK_3zO5PdW-7w0BdhYUMSQnYySX6zmfyGkBe1zLE1CZ0YmJkJr9ysTehMJU0KtYytbMtF4Q96Pjenp-3HtVBf6BM20AMPgtsPQQcNNgTPDqnswKBqmaujgJVXRccKNGK6XTOmyhosVK1KeNYG70pLQEETN2mz_z30P9_UjUKC0rXdqJD2b0OafzpMrgPZshMd3Sa3RghJD4au3yHXUneX3DgZD8nvkeO5K2Qa9CuME6BICs_qqJ8GfC3pSKfaU_wPC5kwdJcL95o6SPeJol6m_j75cvTu8-HxbAyYMAsKmTYbnxReiRYmaK5z8EL41mnma5ODgzGJvAl1BkjEWcRDFjCWYk7eeMB5Hub-A7LTnXXpEaE5wsqTnUwxQyPc-2yYNyB55pT0Tlbk5UpwNoxs4hjU4ocdeJAbi0K2RcgVeT7V_TVwaGyt9RblP9VA3uuSAdpgR22w_9KGiuyuRs-Ok7G3AOEUrFyM8-3FAIKgHSPqijybimGW4dGJ69LZBdQRGonglIQmHg66MHWUcyGRJb8iekNLNr5ks6RbfCtM3gbtcQZtvir69Bfp2PeHn05K6vH_kNMTcrNB55zigrRLds6XF2mPXA-_zxf98mmZS1fHJh_Z priority: 102 providerName: Directory of Open Access Journals – databaseName: Wiley Online Library Open Access dbid: 24P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3daxQxEB9qFfGlfutqlYi-KJ7dbDa7WfBFi6WIPQoq9C3ks72ie3LbFv98Z7J7Ww8PQYSFDclsNsnMJJNk8gvACy6jb1QgJ4ZcTUpbmUkTyJlKquC49I1s0kHhT_V0qo6OmsMNeLs8C9PjQ4wLbqQZqb8mBTe227kEDT113fc3vKhkcwWuci5qkumiPBxXWAhKvEpXtBZ0XlqiJTTikxY7l5-vjEgJuH-dtfmn0-TvxmwajfZu_l89bsHWYIWyd73Y3IaN0N6B6wfDPvtd2J-ahMfBjpHV-AuGz9JbgDl6LdiAyNoxWsrFSOT-z5l5zQyGu8BItEN3D77uffiyuz8Z7lyYuIrAOgsbKjpVXSpXizo6W5a2MXVuuYrOIFu9KByPaFWJ3NM-Dc63fAxWWTQVLXYf92GznbfhIbDosfOKRgYfMRNhbVS5VbnhuamkNTKDl8t2124AJKd7Mb7pHkq50NQ0OjVNBs9H2h89DMdaqvfEvpGCoLNTxHxxrAdN1M7VrsZJqYiGsBFxht5gmXyJQ3nlTW4y2F4yXw_63Gm0Aivs_HIh1iejHYX5qJJn8GxMRkWl3RfThvk50pQ1YclVErN40IvSWFAhSklA-xnUK0K2UpPVlHZ2ksDAFU3pc8zzVRKyv7SO_rj7-SCFHv0L8WO4UZAfT_JW2obNs8V5eALX3MXZrFs8TSr3C4CpLYo priority: 102 providerName: Wiley-Blackwell |
| Title | Natural ghrelin in advanced cancer patients with cachexia, a case series |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcsm.12659 https://www.ncbi.nlm.nih.gov/pubmed/33452750 https://www.proquest.com/docview/2516183033 https://www.proquest.com/docview/2820839841 https://www.proquest.com/docview/2478595653 https://pubmed.ncbi.nlm.nih.gov/PMC8061403 https://doaj.org/article/cc7c74483fa440438390a1d40366da0a |
| Volume | 12 |
| WOSCitedRecordID | wos000607783100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Health & Medical Collection (ProQuest) customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: 7X7 dateStart: 20100901 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: BENPR dateStart: 20100901 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: PIMPY dateStart: 20100901 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: WIN dateStart: 20100101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Open Access customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: 24P dateStart: 20100101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RFiEuvKGBsgqCC4jQvBw7J0SrVi1io4iHWE6R7dhlK8iWTYv4-cx4vVFXrHpBivKyZcWZ8XhmPP4G4EXCbFsKQ0EMsYhyVcioNBRMxYTRCWtLVrqNwh94VYnJpKy9w633YZVLmegEdTvT5CPfRdMAtYVS5Mnbs18RZY2i1VWfQmMDtihtNvE5n_DBx0Jg4oVL0prSjmmGutCAUJrunur-55skLQim9NKc5KD71-mb_4ZNXlZn3Xx0ePt_e3IHbnlNNHy3YJ27cM109-DG2K-134ejSjpMjvAEyY3KaIjHMmIg1HSZhx6VtQ_JnYsvkQP-TOXrUOJ9b0Jib9M_gC-HB5_3jyKfdyHSBQF2psoUtLM6F5pn3GqV56qUPFaJsFoiadss1YlFzSqLW1qrQZurtUYJheqiQhHyEDa7WWe2IbQtCjArmWktNpIpZUWsRCyTWBZMSRbAy-Wfb7QHJafcGD-aBZxy2hCVGkelAJ4Pdc8WUBxra-0RAYcaBJ_tXszmJ40fjY3WXHM0TDMrCR8RrfQSv6nNcTovWhnLAHaWpGv8mO4b1AQLFIBxlq0vHsgawLOhGAcrrcDIzswusE7OCU-uYNjEowUzDR-aZTkjsP0A-AqbrfRktaSbfneA4ILM-hjbfOUY8oq_07zf_zR2d4-v7sMTuJlS9I6LUdqBzfP5hXkK1_Xv82k_H8FGmtcjN9jcWYxga--gqj-OnE8Dn-rjcf0Nn74eV38BgVs1tA |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Zb9QwEB6VgoAX7iNQIAh4ADU0t50HhKBQbenuCqlF2jfXV8oiyJZNy_Gn-I3MOIe6YtW3PiBFShRblh3PTL6xx98API2y0hTcUhBDyINU5TIoLAVTZdzqKDNFVriDwkM2HvPJpPi4An-6szAUVtnZRGeozUzTGvkGugaIFgqeRq8PvweUNYp2V7sUGo1Y7NjfP9Flq19tv8P5fRbHW-_3NgdBm1Ug0DnRUcbK5nRuOOWaJazUKk1VIVmoIl5qiR03SayjEnFDEhraiUCPwpRWcYVgSKGCYLvn4DzacUbOHpuwfk2HyMtzlxQ2phPaGWKvnhE13vii628vozgnWtQT_0CXKmAZvv03TPMkfHb_v62r_9uXuwZXWqTtv2lU4zqs2OoGXBy1sQQ3YTCWjnPEP0BxRrDt49VFRPiabnO_ZZ2tfVquxpco4b-mct2X-Fxbn9TX1rfg05mM4zasVrPK3gW_NGigS5lZU2IjiVIlDxUPZRTKPFMy8-B5N9NCt6TrlPvjq2joomNBUiGcVHjwpK972FCNLK31lgSmr0H04O7FbH4gWmsjtGaaoeOdlJL4HxOcfuyTSRGu5EaG0oO1TlREa7NqgUg3RwMfJsny4l6MPHjcF6Mxoh0mWdnZMdZJGfHl5Rk2cacR3r6jSZJmlEzAA7Yg1gsjWSyppp8d4TmnZYsQ23zhFOCUryM-bO6O3NO908fwCC4N9kZDMdwe79yHyzFFKrl4rDVYPZof2wdwQf84mtbzh07Ffdg_a834Cxk4idM |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VLaq48H4ECgQBBxBhEzsP54AQtKy6tLtaCZDKKdiOXRbBbtm0PP4av44Z56GuWPXWA1KkRLFlxck3k8_2-BuAR1Fiy1wYCmIIRRCrVAa5oWCqRBgdJWWe5G6j8F42Hov9_XyyBn_avTAUVtn6ROeoy7mmOfI-Dg2QLeQijvq2CYuYbA9eHn4PKIMUrbS26TRqiOya3z9x-Fa9GG7jt37M2ODN-62doMkwEOiUpCmZMintIY6FznhmtYpjlcssVJGwWmInSs50ZJFD8LCkVQkcXZTWKKGQGCk0Fmz3HKwjJY9ZD9Ynw9HkYzfDQ1LmqUsRy2i_doJMrNNHZf0vuvr2PGIpiaSe-CO6xAGr2O6_QZsnybT7Gw4u_c_v8TJcbDi4_6o2miuwZmZXYWPURBlcg52xdGok_gECHWm4j0cbK-FrOi38Ro-28mkiG28i9n9N5TNf4nVlfDJsU12HD2fSjxvQm81n5hb4tkTXbWViSouNcKWsCJUIZRTKNFEy8eBJ-9UL3cixU1aQr0UtJM0KQkjhEOLBw67uYS1CsrLWawJPV4OEw92N-eKgaPxQoXWmMxyScytJGZIjFPCZyhiJTFrKUHqw2cKmaLxZVSAHTtH1h5yvLu4g5cGDrhjdFK09yZmZH2OdOCMlvTTBJm7WQO4elPM4oTQDHmRLEF_qyXLJbPrZSaELmtAIsc2nzhhOeTvF2613I3d1-_Q-3IcNNIhibzjevQMXGIUwuS2om9A7Whybu3Be_ziaVot7jb378OmsTeMvNGmUJA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Natural+ghrelin+in+advanced+cancer+patients+with+cachexia%2C+a+case+series&rft.jtitle=Journal+of+cachexia%2C+sarcopenia+and+muscle&rft.au=Blum%2C+David&rft.au=Susanne+de+Wolf-Linder&rft.au=Oberholzer%2C+Rolf&rft.au=Br%C3%A4ndle%2C+Michael&rft.date=2021-04-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=2190-5991&rft.eissn=2190-6009&rft.volume=12&rft.issue=2&rft.spage=506&rft.epage=516&rft_id=info:doi/10.1002%2Fjcsm.12659&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2190-5991&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2190-5991&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2190-5991&client=summon |